AgenTus Therapeutics, a biopharmaceutical company, is focused on the discovery, development, and commercialization of breakthrough “living drugs” to advance cures for cancer patients. AgenTus will employ naturally-derived and engineered receptors, specifically T Cell Receptors (TCRs) and Chimeric Antigen Receptors (CARs), designed to supercharge human immune effector cells to seek and destroy cancer. AgenTus will also aim to advance adoptive cell therapy formats which would enable off-the-shelf living drugs.
AgenTus Therapeutics, Inc.
AgenTus Therapeutics is working to discover and develop CAR and TCR based living drugs and advance them towards the clinic to treat patients with solid tumors and hematologic cancers.
AgenTus Therapeutics is subsidiary company of Agenus Inc. (NASDAQ: AGEN), and is established for Agenus cell therapy business. AgenTus has licensed intellectual property assets from Agenus and has its own management team and governance.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/agentustherapeutics” connections=”true” suffix=””]
AgenTus proprietary state-of-the-art drug discovery engine, T-RxTM Platform technology, enables rapid discovery of T cell receptors (TCRs) and Chimeric Antigen Receptors (CARs). AgenTus is developing promising phosphopeptide tumor targets (PTTs), which are a large class of cancer-specific neo-antigens and are shared amongst many cancers, unlike most mutation-based neo-antigens. These neo-antigens are recognized by TCRs which can be engineered into living drugs.